These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32070133)

  • 1. The costs of cancer drugs.
    Begg CB
    Clin Trials; 2020 Apr; 17(2):118. PubMed ID: 32070133
    [No Abstract]   [Full Text] [Related]  

  • 2. Consortium Outlines 3 Solutions to Maximize the Benefit and Affordability of Targeted Cancer Drugs.
    Cancer; 2018 Aug; 124(16):3283. PubMed ID: 30141838
    [No Abstract]   [Full Text] [Related]  

  • 3. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
    Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
    J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated costs of pivotal trials for U.S. Food and Drug Administration-approved cancer drugs, 2015-2017.
    Hsiue EH; Moore TJ; Alexander GC
    Clin Trials; 2020 Apr; 17(2):119-125. PubMed ID: 32114790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117395
    [No Abstract]   [Full Text] [Related]  

  • 6. Paying for Cancer Drugs That Prove Their Benefit.
    Frank RG; Emanuel EJ
    JAMA; 2021 Oct; 326(16):1579-1580. PubMed ID: 34633420
    [No Abstract]   [Full Text] [Related]  

  • 7. Expensive cancer therapies: unintended effects.
    Delude CM
    J Natl Cancer Inst; 2015 Jan; 107(1):497. PubMed ID: 25564602
    [No Abstract]   [Full Text] [Related]  

  • 8. Optimum cancer care--an unaffordable goal?
    Ludwig H
    Lancet Oncol; 2004 Sep; 5(9):529-30. PubMed ID: 15337480
    [No Abstract]   [Full Text] [Related]  

  • 9. Innovative New Drugs for Serious Nonlethal Diseases: The Cost to Develop and the Cost to Buy.
    Eaglstein WH
    JAMA Dermatol; 2016 Feb; 152(2):139-40. PubMed ID: 26606648
    [No Abstract]   [Full Text] [Related]  

  • 10. Upcoming market catalysts in Q4 2020.
    Pablos L
    Nat Rev Drug Discov; 2020 Oct; 19(10):661. PubMed ID: 32901130
    [No Abstract]   [Full Text] [Related]  

  • 11. Tackling Cost: A Prescription for Spending Wisely.
    Tempero M
    J Natl Compr Canc Netw; 2019 Jun; 17(6):633. PubMed ID: 31200360
    [No Abstract]   [Full Text] [Related]  

  • 12. How should we assess the clinical and cost effectiveness of histology independent cancer drugs?
    Cooper S; Bouvy JC; Baker L; Maignen F; Jonsson P; Clark P; Palmer S; Boysen M; Crabb N
    BMJ; 2020 Jan; 368():l6435. PubMed ID: 31896539
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug.
    Bach PB; Giralt SA; Saltz LB
    JAMA; 2017 Nov; 318(19):1861-1862. PubMed ID: 28975266
    [No Abstract]   [Full Text] [Related]  

  • 14. Can We Find the Positive in Negative Clinical Trials?
    Allegra CJ; Goodwin PJ; Ganz PA
    J Natl Cancer Inst; 2019 Jul; 111(7):637-638. PubMed ID: 31077298
    [No Abstract]   [Full Text] [Related]  

  • 15. The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable.
    Prasad V; Mailankody S
    Mayo Clin Proc; 2016 Jun; 91(6):707-12. PubMed ID: 27261866
    [No Abstract]   [Full Text] [Related]  

  • 16. Oncology drugs enter the US market faster than in Europe but cost more.
    Mitka M
    JAMA; 2012 Aug; 308(6):555. PubMed ID: 22871850
    [No Abstract]   [Full Text] [Related]  

  • 17. Market spiral pricing of cancer drugs.
    Light DW; Kantarjian H
    Cancer; 2013 Nov; 119(22):3900-2. PubMed ID: 24002792
    [No Abstract]   [Full Text] [Related]  

  • 18. Demand grows for early access to promising cancer drugs.
    Baldwin J
    J Natl Cancer Inst; 2002 Nov; 94(22):1668-70. PubMed ID: 12441318
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacoeconomic analyses make way into oncology.
    Amber D
    J Natl Cancer Inst; 2000 Aug; 92(15):1204-5. PubMed ID: 10922402
    [No Abstract]   [Full Text] [Related]  

  • 20. Cancer chemotherapy: a rapidly moving train.
    Shader RI
    Clin Ther; 2013 Sep; 35(9):1253-4. PubMed ID: 24054701
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.